# A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of AZD4144 in Participants With Severe Renal Impairment, End-stage Kidney Disease, and in Healthy Participants

> **NCT06693765** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 41 (actual)

## Conditions studied

- Renal Impairment
- End-stage Kidney Disease
- Healthy Participants

## Interventions

- **DRUG:** AZD4144

## Key facts

- **NCT ID:** NCT06693765
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-11-18
- **Primary completion:** 2025-04-23
- **Final completion:** 2025-04-23
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2026-04-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06693765

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06693765, "A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of AZD4144 in Participants With Severe Renal Impairment, End-stage Kidney Disease, and in Healthy Participants". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06693765. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*